Scientific Info and Patent Analysis Grp 4Q2016 Patent Surveillance - Anti-CD40 dAb (BMS-986090)
Patent Analysis Report
To:Angela Guo Date: January 12, 2017
ST00001816
Update for 4Q2016
From: Rohit Agarwal
Intellectual Property and R&D Solutions
Evalueserve, India
+91 124 463 9923
Therapeutic Area / Project:
Immunology / Anti-CD40 dAb (BMS-986090)
Type of Search:
Q4, 2016 PATENT SURVEILLANCE UPDATE.
Object of Search:
To identify patents/publications that mention anti-CD40 dAb published from October 01, 2016 to December 31, 2016.
Note: Only new INPADOC patent families published in the given period of time are considered for this surveillance alert.
Sources Searched:
PatBase
Summary of Search Strategy
String No. / Search Strategy / LogicS1 / CD40 OR (CD40L RECEPTOR) OR TNFRSF5 OR CDW40 OR BP50 OR (TNF RECEPTOR SUPERFAMILY MEMBER "5") OR (TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER "5") OR MGC9013 / CD40 related terms
S2 / (BMS986090 OR (BMS "986090") OR ASKP1240 OR (ASKP "1240") OR LUCATUMUMAB OR BI655064 OR (BI "655064") OR FFP102 OR (FFP "102") OR (ANTI PTT273) OR ADC1013 OR (ADC "1013") OR APX005 OR (APX "005") OR 5C11OR ("5" C "11") OR PG120 OR (PG "120") OR TENELIXIMAB OR DACETUZUMAB OR TORALIZUMAB OR RUPLIZUMAB OR 4D11 OR ("4" D "11") OR CHIR12.22 OR HCD122 OR (HCD "122" ) OR 5D12 OR ("5" D "12") OR EPI0050 OR (EPI "0050") OR BMS224819 OR (BMS "224819") OR CHI220 OR (CHI "220")OR PRO64553 OR (PRO "64553") OR RG3636 OR (RG "3636") OR SGN11 OR (SGN "11") OR SGN12 OR (SGN "12") OR SGN14 or (SGN "14") OR SGN18 OR (SGN "18") OR SGN40 OR (SGN "40") OR HUS2C6 OR E6040 OR (E "6040") OR IDEC131OR (IDEC "131") OR ANTOVA) / Anti-CD40 mAb related drugs
S3 / S1 OR S2 –Title, Abstract & Claims
Summary of Results
24 references have been identified as interesting in the period from October 01, 2016 to December 31, 2016.
Note: Patent references claiming the following have been considered as non-interesting –
- RNA based therapeutic moiety wherein the RNA encodes antibody to CD40;
- Antibody functioning specifically as CD40 agonist
Copies of WO, EP, & US granted patents & patent applications can be downloaded immediately to your desktop by clicking (or use Control-click) on the patent number hyperlinks provided in this report. Occasionally, a patent application number will be incorrectly linked and will not lead to a relevant document. Patent application numbers can usually be recognized by their format.
- Note: You can now directly access the patent documents within the patent search report. By pressing the CTRL key and mouse-clicking the highlighted patent number simultaneously, the pdf document will open up for your review. Please note that there may be a few minutes lag-time when opening the document, depending on network traffic and/or size of the patent. Patents from major patenting authorities (US, EP, WO) are linked in this report. Patents from other select countries (e.g. AU, CA , FR, GB, DE, JP, CH) or from all countries cited in the report can also be linked, if necessary.
- Note: There is a possibility of patent application numbers being hyperlinked within the patent family. These hyperlinks are a result of a “bug” in the software and should be ignored. They will not link to the corresponding application.
If needed, copies of any other patents can usually be obtained from PatBase.
Copies of journal articles may be available by clicking (or use Control-click) on the hyperlinks provided in this report, or from our Electronic Journal collection on Cybrary. They can also be requested using our online photocopy request form
The material in this search report is for in-house use only and is subject to copyright law and policies. In order to comply with copyright law and policies, DO NOT Distribute this report without permission. Contact
Rohit Agarwal if you have any questions.
The BMS Patent Department must be contacted if the patent information provided is to be used for any type of exclusivity or forecast analysis.
Table of Contents
Patent records that may be of interest
WO2016176089
WO2016154585
WO2016180781
WO2016187068
WO2016196314
WO2016193680
WO2016196377
WO2016201300
WO2016210447
US20160375108
US2016376371
WO2016209936
WO2016191305
WO2016196344
WO2016200782
WO2016164502
WO2016168149
WO2016197204
WO2016205551A2
WO2016205566
WO2016176761
US20160347857
WO2016200881
WO2016181357
Patent records that may be of interest
Reference 1: WO2016176089A1
Publication No. / WO2016176089A1Title / METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE
Assignee / KARDIATONOS
Abstract / A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound. A method of treating multiple disease causes, by administering a glycocalyx restoring and maintaining compound to an individual, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage. A method of treating cardiovascular disease. A method of restoring the glycocalyx. A method of reversing inflammation. A method of reversing oxidative damage. A method of treating any disease involving a membrane that has a glycocalyx. A method of treating multiple disease causes. A method of restoring the structural and functional integrity of receptors in the glycocalyx. A method of restoring the glycocalyx and receptors therein and potentiating drug response. A composition for treating disease including the glycocalyx restoring and maintaining compound and an antibody. A composition for treating cardiovascular disease including the glycocalyx restoring and maintaining compound and a MAb anti- PCSK9.
Text from the document / Claims:
37. A method of restoring the glycocalyx and receptors therein and potentiating drug response, including the steps of: administering a glycocalyx restoring and maintaining compound and an antibody to an individual suffering from disease; restoring the glycocalyx; restoring receptors in the glycocalyx; and potentiating the response of the antibody.
40. The method of claim 37, wherein the disease is chosen from the group consisting of autoimmune diseases, cancers, metabolic disorders, and infectious diseases.
41. A composition for treating disease comprising a glycocalyx restoring and maintaining compound and an antibody.
44. The composition of claim 41 , wherein said antibody is chosen from the group consisting of…….lucatumumab…..
Inventor / Tunac Josefino B; Kohn Kenneth I
Publication Date / 20161103
Earliest Priority Date / 20150429
Patbase Family Members / WO2016176089A1;
Reference 2: WO2016154585A1
Publication No. / WO2016154585A1Title / ANTI-MICA ANTIGEN BINDING FRAGMENTS, FUSION MOLECULES, CELLS WHICH EXPRESS AND METHODS OF USING
Assignee / SENTMAN CHARLES; BATTLES MICHAEL
Abstract / Antigen binding fragments, chimeric antigen receptors, and bi-specific T-cell engagers having specificity for MICA and methods for using the same in the diagnosis and treatment of disorders associated with MICA and/or MICB expression are provided.
Text from the document / Claims:
1. An antibody or antigen binding fragment that specifically binds to major histocompatibility complex class I chain-related gene A (MICA) selected from the following:
(i) an anti-MICA antibody or antibody fragment that comprises the variable heavy ("VH") CDR1, 2 and 3 polypeptides of SEQ ID NO:35, 36 and 22 respectively; and the variable light ("VL") CDRs of SEQ ID NO:26, 28 and 37 respectively;…….
13. The anti-MICA antibody or antigen binding fragment, CAR or BiTE® or other fusion of any of the foregoing claims which comprises an antibody or antigen binding fragment or ligand which specifically binds to an antigen expressed on an immune effector cell selected from ….. CD40, PD-1, ICOS, lymphocyte function-associated antigen- 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and CD83.
Inventor / Sentman Charles; Battles Michael
Publication Date / 20160929
Earliest Priority Date / 20150326
Patbase Family Members / WO2016154585A1
Reference 3: WO2016180781A1
Publication No. / WO2016180781A1Title / COMBINATION THERAPY OF MESOTHELIOMA
Assignee / COVRE ALESSIA; MAIO MICHELE; CORAL SANDRA
Abstract / The present invention relates to a method of treating and/or preventing malignant mesothelioma comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.
Text from the document / Claims:
1. A DNA hypomethylatmg agent and at least one immunomodulatory agent and/or optionally at least one targeted therapy agent for use in the treatment and/or in the prevention of malignant mesothelioma.
3. The DNA hypomethylatmg agent and the at least one immunomodulatory agent and/or optionally the least one targeted therapy agent for use according to claim 1 or 2 wherein the immunomodulatory agent is selected from the group consisting of: immunomodulating antibody, cancer vaccine, therapeutic cytokine, cellular therapy.
4. The DNA hypomethylatmg agent and the at least one immunomodulatory agent and/or optionally the least one targeted therapy agent for use according to claim 3 wherein the immunomodulating antibody is selected from the group consisting of: an anti-CTLA-4, an anti-PDL-1, an anti-PDL-2, an anti-PDl, an anti-CD137, an anti-CD40, anti-LAG3, anti-TIM3, anti-KIR, anti-GITR, anti-ICOS or an anti-OX-40 antibody.
Inventor / Covre Alessia; Maio Michele; Coral Sandra
Publication Date / 20161117
Earliest Priority Date / 20150508
Patbase Family Members / WO2016180781A1;
Reference 4: WO2016187068A1
Publication No. / WO2016187068A1Title / ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES
Assignee / GENERAL HOSPITAL
Abstract / Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T- lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
Text from the document / Claims:
161 . An antibody or antigen-binding fragment thereof that specifically binds a tumor necrosis factor receptor superfamily (TNFRS) member in an anti-parallel dimer conformation, and, optionally, wherein said antibody or antigen-binding fragment thereof contains a non-native constant region.
169. The antibody or antigen-binding fragment thereof of any one of claims 161 -168, wherein said TNFRS member is selected from the group consisting of ....CD40....
176. A composition comprising the antibody or antigen-binding fragment thereof of any one of claims 161 -170 for treating a disease mediated by signaling through a TNFRS member in a human.
Inventor / Faustman Denise L;
Publication Date / 20161124
Earliest Priority Date / 20150515
Patbase Family Members / WO2016187068A1;
Reference 5: WO2016196314A1
Publication No. / WO2016196314A1Title / ANTI-CD40 ANTIBODIES AND USES THEREOF
Assignee / ABBVIE
Abstract / The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
Text from the document / Claims:
1. An isolated antibody, or antigen binding portion thereof, wherein said antibody, or antigen binding fragment thereof, binds an epitope of human CD40 defined by the topographic regions Cys62-Phe67, Gln79-Cys83, Arg90-Thr99, and Thr24-Cys37 of SEQ ID NO:1.
66. A method for treating a human subject having a disorder in which CD40 is detrimental comprising administering an effective amount of the anti-CD40 antibody, or antigen binding portion thereof, of any one of claims 1-45 to the subject.
Inventor / Mcrae Bradford L; Argiriadi Maria A; Hsieh Chung Ming; Benatuil Lorenzo;
Publication Date / 20161208
Earliest Priority Date / 20150529
Patbase Family Members / US2016347850AA; WO2016196314A1;
Reference 6: WO2016193680A1
Publication No. / WO2016193680A1Title / COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
Assignee / JONES NICHOLAS ANDREW ; BERGENBIO
Abstract / The present invention concerns an Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
Text from the document / Claims:
1. An Axl inhibitor and one or more immune checkpoint (activity) modulators, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators are administered concurrently, separately or sequentially.
8. The Axl inhibitor and one or more immune checkpoint (activity) modulators for use according to any one of claims 1 to 5, wherein the one or more immune checkpoint (activity) modulators are selected from the group consisting of anti-CTLA-4 antibodies, anti-PD-1 antibodies, anti-PD-Ll antibodies, anti-4-lBB antibodies, anti-OX-40 antibodies, anti-GITR antibodies, anti-CD27 antibodies, anti-CD28 antibodies, anti-CD40 antibodies, anti-LAG3 antibodies, anti-ICOS antibodies, anti-TWEAKR antibodies, anti- HVEM antibodies, anti-TIM-1 antibodies, anti-TIM-3 antibodies, anti-VISTA antibodies, and anti-TIGIT antibodies.
Inventor / Gausdal Gro; Lorens James Bradley;
Publication Date / 20161208
Earliest Priority Date / 20150529
Patbase Family Members / GB201509338A0; GB201516442A0; WO2016193680A1;
Reference 7: WO2016196377A1
Publication No. / WO2016196377A1Title / COMBINATION CANCER THERAPIES
Assignee / LOUIS CHRYSTAL U ; ADAMS SHARLENE ; MERRIMACK PHARMACEUTICALS INC ; FINN GREGORY J ;
Abstract / The disclosure provides methods of treatment for cancer in patients using bispecific anti-IGF-lR, anti-ErbB3 antibodies in combination with one or more therapeutic agents that impede regulatory T-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human PD-L1.
Text from the document / Claims:
1. The use of a therapeutically effective amount of istiratumab in combination with an immunomodulatory agent to treat cancer in a human patient, where the immunomodulatory agent is selected from the group consisting of: (a) an agonistic anti-receptor antibody that immunospecifically binds human OX40, CD40,GITR, CD27, ICOS, or 4-1BB; (b) an antagonistic anti-receptor antibody that immunospecifically binds human CTLA-4, PD-1, PD- Ll, TIM-3, BTLA, VISTA, LAG-3, KIR, CD47,CD25, B7-H3, or B7-H4; and (c) an anti- ligand antibody that blocks function of IL-6, IL-10, TGF , angiopoetin-2, VEGF, IL-17, IL-23, or TNFa.
Inventor / Curley Michael; Louis Chrystal U; Adams Sharlene; Lugovskoy Alexey Alexandrovich; Finn Gregory J;
Publication Date / 20161208
Earliest Priority Date / 20150529
Patbase Family Members / WO2016196377A1;
Reference 8: WO2016201300A1
Publication No. / WO2016201300A1Title / DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS
Assignee / IMMUNOMEDICS
Abstract / The present invention concerns CAR, CAR-T and CAR-NK constructs, preferably comprising a scFv antibody fragment against a disease-associated antigen or a hapten. More preferably, the antigen is a TAA, such as Trop-2. The constructs may be administered to a subject with a disease, such as cancer, autoimmune disease, or immune dysfunction disease, to induce an immune response against disease-associated cells. Where the constructs bind to a hapten, the subject is first treated with a hapten-conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments, such as debulking procedures (e.g., surgery, chemotherapy, radiation therapy) or coadministration of other agents. More preferably, administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease-associated antigen. Most preferably, an antibody against CD74 or HLA-DR is administered to reduce systemic immunotoxicity induced by the constructs.
Text from the document / Claims:
1. A method of inducing an immune response to a disease comprising: a) predosing a subject with an unconjugated antibody against a disease-associated antigen; and b) administering to the subject a chimeric antigen receptor transfected T cell (CAR-T) or chimeric antigen receptor transfected K cell (CAR- K), wherein the chimeric antigen receptor (CAR) comprises a targeting antibody fragment against the same antigen.
6. The method of claim 1, wherein the antigen is a tumor-associated antigen (TAA) and the disease is cancer.
7. The method of claim 6, wherein the TAA is selected from the group consisting of....CD40...
Inventor / Chang Chien Hsing; Liu Donglin; Goldenberg David M;
Publication Date / 20161215
Earliest Priority Date / 20150612
Patbase Family Members / US2016361360AA; WO2016201300A1;
Reference 9: WO2016210447A1
Publication No. / WO2016210447A1Title / MASKING CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TUMOR-SPECIFIC ACTIVATION
Assignee / UNIVERSITY OF SOUTHERN CALIFORNIA
Abstract / The invention is directed to a masked chimeric antigen receptor, comprising: (a) a masking peptide; (b) one or more antigen-specific targeting domains; (c) an extracellular spacer domain; (d) a transmembrane domain; (e) at least one co-stimulatory domain; and (f) an intracellular signaling domain. The mCARs are activated upon cleavage of the masking peptide.
Text from the document / Claims:
1. A masked chimeric antigen receptor (mCAR), comprising:
a. a masking peptide;
b. antigen-specific targeting domain;
c. a transmembrane domain;
d. at least one co-stimulatory domain; and
e. an intracellular signaling domain, wherein the antigen-specific targeting domain comprises an antigen-specific single chain Fv (scFv) fragment.
16. The masked chimeric antigen receptor of claim 1, wherein the antigen-specific targeting domain targets an antigen selected from the group consisting of antigens specific for cancer, an inflammatory disease, a neuronal disorder, diabetes, a cardiovascular disease, an infectious disease, an autoimmune disease, and combinations thereof.
17. The masked chimeric antigen receptor of claim 16, wherein the antigen-specific for cancer comprises any one or more of….CD40….
36. A method for treating a disease in a subject in need thereof, comprising: providing a composition of claim 1; and administering a therapeutically effective amount of the composition to the subject, so as to treat the disease, wherein the antigen-specific targeting domain is associated with the disease.
Inventor / Wang Pin; Han Xiaolu; Bryson Paul
Publication Date / 20161229
Earliest Priority Date / 20150626
Patbase Family Members / WO2016210447A1;
Reference 10: US20160375108A1
Publication No. / US20160375108A1Title / COMPOSITIONS AND METHODS OF USE OF IMMUNOTOXINS COMPRISING RANPIRNASE (RAP) SHOW POTENT CYTOTOXIC ACTIVITY
Assignee / IMMUNOMEDICS; IBC PHARMA
Abstract / The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.
Text from the document / Claims:
1. A method of treating cancer, comprising: a) obtaining a complex comprising (i) a first fusion protein comprising a toxin attached to a DDD (dimerization and docking domain) moiety from human protein kinase A (PKA) regulatory subunit RI.alpha., RI.beta., RII.alpha. or RII.beta., wherein the toxin is selected from the group consisting of ranpirnase (Rap), saporin, diphtheria toxin, gelonin, Pseudomonas exotoxin; and (ii) a second fusion protein comprising an antibody or antigen binding antibody fragment attached to an AD (anchoring domain) moiety from an AKAP protein, wherein the antibody or antibody fragment binds to a human tumor-associated antigen (TAA); and b) administering the complex to a human subject with cancer; wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex.
2. The method of claim 1, wherein the TAA is selected from the group consisting of .....CD40.....
Inventor / Chang; Chien-Hsing; Goldenberg; David M.; Rossi; Edmund A.;
Publication Date / 20161229
Earliest Priority Date / 20040213
Patbase Family Members / US2016375108A1
Reference 11: US2016376371A1
Publication No. / US2016376371A1Title / ANTIBODIES TO CD40
Assignee / BRISTOL-MYERS SQUIBB
Abstract / Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcϒRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Text from the document / Claim:
1. An isolated antibody, or antigen binding portion thereof, that specifically binds to human CD40 and competes for binding to human CD40 in a cross-blocking assay with one or more of antibodies selected from the group consisting of 12D6 (SEQ ID NOs: 3 and 4), 5F11 (SEQ ID NOs: 23 and 24), 8E8 (SEQ ID NOs: 40 and 41), 5G7 (SEQ ID NOs: 52 and 53), and 19G3 (SEQ ID NOs: 58 and 59).
Inventor / Barnhart Bryan C; Devaux Brigitte; Yamniuk Aaron P; Okada Shannon L; Stevens Brenda L
Publication Date / 20161229
Earliest Priority Date / 20150629
Patbase Family Members / US2016376371A1; WO17004006A1; WO17004016A1;
Reference 12: WO2016209936A1